NCT07369154Phase 3Recruiting

52-week Open Label Safety-Tolerability Study

Study sponsor: LB Pharmaceuticals Inc. · LBRX

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2028-12Estimated
Enrollment · participants900Estimated
Source updated2026-09-09Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Recruitment status changed

Before: Not yet recruiting. After: Recruiting.

Check registry source